Ellen Hendrikse
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ellen Hendrikse has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Andor W. J. M. Glaudemans
Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
2 shared publications - Alexandre Wagner Silva de Souza
Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP), São Paulo 04023-062, SP, Brazil
1 shared publication - Anne Jetske Boer1 shared publication
Berit D. Nielsen
Department of Rheumatology, Aarhus University Hospital, Denmark (B.D.N.).
1 shared publication- Bonnia Liu
Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Department of Rheumatology, Austin Health, Melbourne, Australia; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia; Department of Nuclear Medicine and PET, Royal Melbourne Hospital, Melbourne, Australia
1 shared publication - Chris W. J. van der Weijden
University Medical Center Groningen, University of Groningen
1 shared publication
Latest Publications
- Open Access
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Sex Differences in Age-Related Changes in Striatal Dopamine Synthesis: Insights from 370 [¹⁸F]FDOPA PET Scans
Background: During the menopausal transition, women are at increased risk for mental health conditions, compared to premenopausal women and age-matched men, while existing psychiatric disorders tend to worsen around menopause. This increased risk is thought to be related to a decline in sex steroids, which may influence blood flow and metabolism in the brain. In addition, rodent studies demonstrated a relationship between sex steroids and striatal dopamine synthesis, but this relationship has not been replicated in humans. This study investigated age and sex differences in tracer delivery to the brain and striatal dopamine synthesis in 370 patients aged 25-85 years, who underwent [18F]FDOPA PET.Methods: Whole body [¹⁸F]FDOPA PET scans were obtained from patients without neurological or psychiatric disease at the University Medical Centre Groningen (UMCG) between December 2017 and January 2024 in clinical context of suspected neuroendocrine tumors (NETs). [¹⁸F]FDOPA delivery to the brain and striatal dopamine synthesis were compared between sexes, stratified by age decades. Findings: Significant sex differences in tracer delivery, expressed as standardized uptake value (SUV), in striatum, caudate, putamen, ventral striatum, and cerebellum (p < 0.0 – p < 0.0001) were observed, starting at perimenopausal age (46-55 year) and persisting with age. After normalization for [¹⁸F]FDOPA uptake in cerebellum, a region devoid of dopamine synthesis, no significant sex differences were observed for striatal regions (p = 0.39 – 1.00).Interpretation: Our data demonstrate changes in cerebral blood flow and/or tracer metabolism starting at perimenopausal age that affect PET tracer delivery to the brain. These results do not support changes in striatal dopamine synthesis around the menopausal transition. This study highlights the need for further investigation of physiological and cerebral changes occurring around menopause to better understand if and how physiological brain changes associated with menopause may worsen mental health in this life phase.
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSex Differences in Age-Related Changes in Striatal Dopamine Synthesis: Insights from 370 [¹⁸F]FDOPA PET Scans
Background: During the menopausal transition, women are at increased risk for mental health conditions, compared to premenopausal women and age-matched men, while existing psychiatric disorders tend to worsen around menopause. This increased risk is thought to be related to a decline in sex steroids, which may influence blood flow and metabolism in the brain. In addition, rodent studies demonstrated a relationship between sex steroids and striatal dopamine synthesis, but this relationship has not been replicated in humans. This study investigated age and sex differences in tracer delivery to the brain and striatal dopamine synthesis in 370 patients aged 25-85 years, who underwent [18F]FDOPA PET.Methods: Whole body [¹⁸F]FDOPA PET scans were obtained from patients without neurological or psychiatric disease at the University Medical Centre Groningen (UMCG) between December 2017 and January 2024 in clinical context of suspected neuroendocrine tumors (NETs). [¹⁸F]FDOPA delivery to the brain and striatal dopamine synthesis were compared between sexes, stratified by age decades. Findings: Significant sex differences in tracer delivery, expressed as standardized uptake value (SUV), in striatum, caudate, putamen, ventral striatum, and cerebellum (p < 0.0 – p < 0.0001) were observed, starting at perimenopausal age (46-55 year) and persisting with age. After normalization for [¹⁸F]FDOPA uptake in cerebellum, a region devoid of dopamine synthesis, no significant sex differences were observed for striatal regions (p = 0.39 – 1.00).Interpretation: Our data demonstrate changes in cerebral blood flow and/or tracer metabolism starting at perimenopausal age that affect PET tracer delivery to the brain. These results do not support changes in striatal dopamine synthesis around the menopausal transition. This study highlights the need for further investigation of physiological and cerebral changes occurring around menopause to better understand if and how physiological brain changes associated with menopause may worsen mental health in this life phase.
- 23 June 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (25) , 2064-2083
Challenges and Future Trends in Large Vessel Vasculitis
Based on the Chapel Hill consensus criteria, the primary forms of vasculitis are classified by the predominant size of the affected blood vessels into large, medium, or small vessels. The two main forms of large vessel vasculitis (LVV) are giant cell arteritis and Takayasu arteritis, both of which are more prevalent in women while showing distinct geographic patterns of prevalence. The pathogenesis of LVV is complex and multifactorial, involving a combination of genetic predisposition, environmental and geographic triggers, immune dysregulation, and aging or (premature) senescence of the immune system and blood vessels. Diagnosis based on clinical presentation alone can be challenging because of the wide variety and often nonspecific symptoms that are associated with LVV. This has prompted the development of novel diagnostic tools to aid patient management, in particular advanced vascular imaging approaches. New therapies targeting specific immune pathways are now becoming available to improve outcomes while limiting the side effects associated with traditional glucocorticoid treatment. Advances in molecular imaging techniques may also enhance our ability to objectively monitor disease and treatment response in patients with LVV. Ongoing research aims to better understand the underlying mechanisms and to develop better targeted therapies for LVV, and to improve patient assessment and life time management. This narrative review will provide an in-depth update on current challenges and future trends in LVV, enhancing our understanding of its pathogenesis, diagnostic features, and management strategies, including disease- and treatment-related cardiovascular complications.
- 23 June 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (25) , 2064-2083
Challenges and Future Trends in Large Vessel Vasculitis
Based on the Chapel Hill consensus criteria, the primary forms of vasculitis are classified by the predominant size of the affected blood vessels into large, medium, or small vessels. The two main forms of large vessel vasculitis (LVV) are giant cell arteritis and Takayasu arteritis, both of which are more prevalent in women while showing distinct geographic patterns of prevalence. The pathogenesis of LVV is complex and multifactorial, involving a combination of genetic predisposition, environmental and geographic triggers, immune dysregulation, and aging or (premature) senescence of the immune system and blood vessels. Diagnosis based on clinical presentation alone can be challenging because of the wide variety and often nonspecific symptoms that are associated with LVV. This has prompted the development of novel diagnostic tools to aid patient management, in particular advanced vascular imaging approaches. New therapies targeting specific immune pathways are now becoming available to improve outcomes while limiting the side effects associated with traditional glucocorticoid treatment. Advances in molecular imaging techniques may also enhance our ability to objectively monitor disease and treatment response in patients with LVV. Ongoing research aims to better understand the underlying mechanisms and to develop better targeted therapies for LVV, and to improve patient assessment and life time management. This narrative review will provide an in-depth update on current challenges and future trends in LVV, enhancing our understanding of its pathogenesis, diagnostic features, and management strategies, including disease- and treatment-related cardiovascular complications.
- Open Access
- 8 April 2026
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 56 (4) , 593-605
PET imaging of polymyalgia rheumatica: update and future trends
- 8 April 2026
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 56 (4) , 593-605
Open AccessPET imaging of polymyalgia rheumatica: update and future trends